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DESIGNER DRUGS

Deaths associated with new designer drug 5-IT
L Nitin Seetohul lecturer in forensic toxicology, Peter D Maskell lecturer in forensic toxicology, Giorgia De Paoli lecturer in forensic toxicology, Derrick J Pounder professor of forensic medicine Centre for Forensic and Legal Medicine, University of Dundee, Dundee DD1 4HN, UK 5-IT or 5-API is the common name for a newly emerging designer drug. 1 It is a positional isomer of the tryptamine drug α-methyltryptamine and has the chemical structure (1H-indol-5-yl)propan-2-amine. Currently not controlled in Europe, it is covered, however, by the federal analogue acts in the USA 2 and Australia. 3
Very little is known about the acute or chronic effects of 5-IT. An oral dose of 20 milligrams is said to produce long lived stimulant effects, including increased heart rate, anorexia, diuresis, and slight hyperthermia for about 12 hours. 4
Recently we identified 5-IT in postmortem blood samples of two young adults. The substance was found in combination with other drugs in one case. In the other, 5-APB/6-APB (a designer drug similar in some respects to the chemical structure of 3,4-methylenedioxyamphetamine (MDA)) was also found. The National Board of Forensic Medicine in Sweden has recently identified the drug in 14 deaths and 5-IT was said to be the direct cause of death in two of these cases. 5 5-IT is inexpensive, easily available online as a so called research chemical and therefore has the potential for becoming a replacement for other recently banned designer drugs. The medical community should be aware of both the availability and use of 5-IT within the UK. The drug needs to be banned, but again regulatory control in the UK will be chasing designer drug innovation.
